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Abstract
Background:
Depression is the most common mental disorder, and suicide is its most serious
consequence. The primary objective of this study was to evaluate preliminary
evidence for the P4 screener as a brief measure to assess potential suicide risk.
Method:
The P4 screener was prospectively evaluated in 2 randomized effectiveness trials
of primary care (January 2005–June 2008; N = 250) and oncology patients
(March 2006–August 2009; N = 309). Potential suicide ideation was assessed at 5
time points in both trials: baseline and 1, 3, 6, and 12 months. The P4 screener
asks about the “4 P’s”: past suicide attempts, suicide plan, probability of
completing suicide, and preventive factors. Patients were classified as minimal,
lower, and higher risk based upon responses to these 4 items.
Results:
A suicide assessment was triggered 1 or more times by 17.6% (44 of 250) of
Stepped Care for Affective Disorders and Musculoskeletal Pain (SCAMP)
participants and 16.5% (51 of 309) of Indiana Cancer Pain and Depression
(INCPAD) participants at some point in the trial. Of the patients who triggered a
suicide assessment, the majority (29 of 44 in SCAMP and 27 of 51 in INCPAD)
were classified as minimal risk by the algorithm. Only 1 (0.4%) of the SCAMP
participants and 5 (1.6%) of the INCPAD participants were classified as higher
risk. Among the latter, the most common factors preventing patients from
attempting suicide were the “4 F’s”: faith, family, future hope, and fear of failing
in their attempt.
Conclusions:
Preliminary findings suggest that the P4 screener may be useful in assessing
potential suicide risk in the clinical care of depressed patients as well as in clinical
research.
Trial Registration:
clinicaltrials.gov Identifier: NCT00118430 (SCAMP) and NCT00313573
(INCPAD)
Suicide is the eleventh leading cause of death in the United States, with roughly
30,000 lives lost per year.  Globally, there were over 1 million deaths to suicide
in 2000, or approximately 16 suicides per 100,000 individuals. Depression is the
most prevalent and disabling mental health disorder and the leading risk factor for
suicide. Other risk factors include alcohol and substance abuse, older age, male
gender, social isolation, family history of suicide, past attempts, access to lethal
arms, hopelessness, and chronic medical and neurologic disorders.
A number of studies have focused on suicidality among adults in primary care,
adolescents,  the elderly,  and cancer patients.  However, these studies
have principally focused on the prevalence of and risk factors for suicidal ideation
rather than an explicit assessment strategy.
To date, there is no single recommended method to screen for suicidality.  There
have been single studies that have used 1 or a few questions inquiring directly
about suicidal ideation.  There are several longer scales such as the Beck
Scale for Suicidal Ideation (21 items),  the Columbia Suicide Severity Rating
Scale (18 items),  the Sheehan Suicide Tracking Scale (8 items),  and the
Nurses’ Global Assessment of Suicide Risk (15 items).  In addition to the length
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of the scales, their scoring is more complicated, and they have often been tested in
psychiatric rather than in general medical populations. A few studies have used
more complex algorithms to assess suicidality.  A simpler algorithm that
helped inform the P4 screener was developed by Cole and colleagues.
Suicidal ideation is often unrecognized in primary care or medical specialty
settings due to an inability of patients to articulate their feelings to their health
care providers and a discomfort among non–mental health clinicians to ask about
such feelings.  The additional concern that asking about suicidal thoughts may
actually trigger suicidal ideation and behavior is unfounded.  Although asking
about suicide when identifying and treating depressed patients is considered
standard of care, competing demands in medical practice create particular barriers
to interview techniques that require prolonged probing.  The sensitivity and
discomfort surrounding suicide assessment and overestimates of how often urgent
mental health referral may be required further accentuate these barriers.
Surprisingly, there is even inconsistency in the degree to which psychiatrists ask
about and document suicidal ideation in routine clinical practice, an omission
which can be improved by the use of brief assessment measures.
Clinical Points
♦The P4 screener assesses suicide risk by asking about the “4 P’s”:
past suicide attempts, a plan, probability of completing suicide, and
preventive factors.
♦Most participants in clinical trials of depressed medical patients who
acknowledge thoughts of self-harm are ultimately classified as low risk
by the P4 screener.
♦To address the need for an efficient yet valid means of assessing
suicide risk in medical populations, this article describes the findings
from 2 randomized controlled trials regarding a brief algorithm that
has evolved over the course of 6 randomized effectiveness depression
trials conducted by our research group in the past decade. Core items
emerged from the first 4 trials leading to a standard algorithm that was
prospectively evaluated in more detail in our 2 most recent trials.
METHOD
Developmental History of the P4 Screener
The P4 screener (Figure 1) was initially developed and refined in 4 earlier
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trials  and subsequently tested in its final form in the 2 most recent trials.
Some of the P4 items were originally developed by Cole and colleagues for use
by primary care physicians.  As summarized in Table 1 all 6 trials were
effectiveness trials conducted in medical populations, of which 4 were situated in
primary care and 2 in specialty settings. A total of 3,523 participants were
enrolled from 146 practices and followed for 6 to 24 months. The intervention
was a collaborative care approach to enhance depression treatment (typically with
a nurse care manager supervised by a physician specialist) in 5 trials and an open-
label active comparator design in 1 trial. The control group received usual care in
4 trials, nonspecific attention in 1 trial, and an active comparator in 1 trial. Only 2
of the trials—IMPACT (Improving Mood-Promoting Access to Collaborative
Treatment)  and RESPECT (Re-Engineering Systems in Primary Care Treatment
of Depression) —have published data related to suicidality among their study
participants, and these trials have focused principally on risk stratification and
predictors as well as the effects of depression treatment rather than on the
algorithm itself.
Each of the 6 trials had a structured assessment for assessing suicide risk that was
triggered when patients endorsed potential thoughts of self-harm during baseline
or follow-up interviews, typically by a positive response to the question about
self-harm on the Hopkins Symptom Checklist 20-item depression scale  (HSCL-
20, item 13), the Patient Health Questionnaire 9-item depression scale  (PHQ-9,
item 9), or the Structured Clinical Interview for DSM-IV-TR Axis I Disorders
(item 9). As shown in the length of algorithms varied considerably among the
trials, ranging from quite brief (3 items in the IMPACT algorithm) to lengthier
(10–16 items in the RESPECT algorithm). However, 4 questions emerged as core
items, all of which were included in algorithms used in the 4 most recent trials.
These 4 core items (the “4 P’s”) include questions about past attempts, suicide
plans, probability of completing suicide, and preventive factors.
Testing of the P4 Screener in the SCAMP and INCPAD Trials
A structured algorithm was used in the SCAMP (Stepped Care for Affective
Disorders and Musculoskeletal Pain) and INCPAD (Indiana Cancer Pain and
Depression) trials on the basis of experience in the first 4 trials. Both trials are
registered in clinicaltrials.gov (identifier: NCT00118430 [SCAMP] and
NCT00313573 [INCPAD]). SCAMP enrolled primary care patients with
clinically significant depression and comorbid chronic musculoskeletal pain from
January 2005 to June 2008. Of 756 eligible patients, 250 consented and were
randomized to a collaborative care intervention or usual care. The intervention
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was administered by a nurse-physician team, which delivered optimized
antidepressant therapy and a pain self-management program. The mean age of the
SCAMP participants was 55.5 years; 52.8% were women; 60.4% were white,
36.4% were black, and 3.2% were other.
INCPAD enrolled patients with cancer-related pain or depression who were
receiving care in community-based oncology practices from March 2006 to
August 2009. Of 616 patients in which eligibility could be ascertained, 405 were
randomized to a telecare-based collaborative care intervention or usual care; 309
of the 405 patients were depressed and are the focus of this article. The
intervention was administered by a nurse-psychiatrist team, which optimized
antidepressant and analgesic management. The mean age of the INCPAD
participants was 55.5 years; 52.8% were women; 79.5% were white, 18.0% were
black, and 2.5% were other.
As shown in the algorithm guided interviewers in both SCAMP and INCPAD to
ask about the 4 P’s—past history, plan, probability, and preventive factors—and
several clarifying questions; the latter were asked at the interviewer's discretion.
An algorithm form was completed if a suicide assessment was triggered at any of
the 5 scheduled research interviews (baseline or 1, 3, 6, or 12 months) or during a
scheduled clinical assessment by a nurse care manager (SCAMP) or by automated
depression monitoring (INCPAD). In addition to the closed-ended questions,
there were 2 open-ended questions that asked patients to describe their plan of
action and any protective factors that prevented them from carrying it out.
Patients in whom the suicide algorithm was triggered were classified into 3 risk
categories based upon responses to the P4 screener questions. Minimal risk
patients were those who had neither a past history nor a suicide plan and also
responded “not at all likely” to the question about probability of an attempt.
Lower risk patients were those who indicated they had a plan and/or past history
but responded “not at all likely” to the question about probability and noted there
were factors preventing them from taking action. Higher risk patients were those
who reported the probability of a suicide attempt as either “somewhat likely” or
“very likely” and/or reported there were no factors preventing them from taking
action.
Analysis
We tabulated the number of times the suicide assessment algorithm was triggered
in the SCAMP and INCPAD trials. Since some patients triggered the suicide
assessment multiple times over the 12-month trials, we also determined the
number of patients who triggered the suicide assessment at least once and the
proportion of patients classified as minimal, lower, and higher risk. Responses to
the 2 open-ended questions about suicide plans and preventive factors were
independently coded by 2 investigators trained in qualitative research. This coding
resulted in 5 categories each for suicide plans (overdose, firearms, vehicular
accidents, cutting self, other) and preventive factors (family, future hope, religious
faith, fear of failure, other).
RESULTS
Frequency of Suicide Assessments
There were a total of 1,144 interviews at the 5 time points in SCAMP and 1,667
in INCPAD. A suicide assessment was triggered in 69 (6%) of the interviews in
SCAMP and 83 (5%) in INCPAD. The likelihood of triggering a suicide
assessment declined slightly after the first month and then remained stable. For
example, the proportion of interviews triggering a suicide assessment in INCPAD
at baseline and 1, 3, 6, and 12 months was 8.1% (25/309), 8.2% (22/269), 5.3%
(13/246), 5.4% (12/223), and 5.5% (11/202), respectively. A similar temporal
pattern was observed in SCAMP.
Suicidal Risk Stratification
Figure 2outlines the risk stratification of patients from both trials who triggered
the suicide algorithm. Since some patients triggered the algorithm more than 1
time during their 5 assessments in the trial, the total number of unique patients
triggering the assessment in is less than the total number of interviews in which an
assessment was triggered (). A suicide assessment was triggered 1 or more times
by 17.6% (44 of 250) of SCAMP participants and 16.5% (51 of 309) of INCPAD
participants. Thus, about 1 in 6 patients in both trials (1 enrolling depressed
primary care patients with chronic pain and the other enrolling depressed patients
with cancer of whom 56% had comorbid pain) triggered a suicide assessment
when interviewed up to 5 times over a 12-month period.
Of the patients who triggered a suicide assessment, the majority (29 of 44 in
SCAMP and 27 of 51 in INCPAD) were classified as minimal risk by our
algorithm, meaning they had no past attempt or current plan and reported the
probability of hurting themselves as “not at all likely.” Most of the remaining
patients were classified as lower risk, meaning that although they reported a past
history and/or plan, they considered the probability of hurting themselves as “not
at all likely” and reported factors preventing them from taking action. Only 1
(0.4%) of the SCAMP patients and 5 (1.6%) of the INCPAD patients were
classified as higher risk, defined as a self-assessed probability of self-harm as
“somewhat likely” or “very likely” and/or an absence of factors preventing the
patient from taking action.
A suicide assessment was triggered during only 1 interview by 65 patients, in 2
interviews by 18 patients, and in 3 or more interviews by 12 patients. In the 30
patients who triggered a suicide assessment more than once, the risk class
remained constant in 19 patients and changed across interviews in 11. The risk
class went down in 4 patients over time, went up in 5, and changed directions
twice in 2.
Of note, there were an additional 250 nondepressed patients with chronic pain in
SCAMP who were assessed at baseline and 3 and 12 months as part of a
secondary cohort study, and there were 96 nondepressed cancer patients with pain
in INCPAD who were assessed at baseline and 1, 3, 6, and 12 months. In both
trials, all participants underwent an identical assessment battery including
depression measures. The number of patients who triggered the suicide
assessment in these nondepressed pain groups was only 7 (2.8%) in SCAMP and
5 (5.2%) in INCPAD, confirming the strong linkage between suicidal ideation and
depression.
Severity of Depression and Suicidal Risk Class
Since some patients triggered a suicide assessment more than once over the 12
months of follow-up in each trial, we examined depression severity at the
interview level. Of 2,391 evaluable interviews in the SCAMP and INCPAD trials,
a suicide assessment was triggered in 144 (6.0%). The mean participant HSCL-20
score across all interviews was 1.42, compared to a mean HSCL-20 score of 2.21
for the 83 interviews classified as minimal risk and 2.37 for the 62 interviews
classified as lower (n = 53) or higher risk (n = 9); the latter 2 categories were
combined because of the small number of interviews in the higher risk category.
Depression was therefore more severe (P < .0001) in patients who triggered a
suicide assessment, but did not differ significantly among the different risk
categories in those who triggered an assessment.
Suicide Plans and Preventive Factors
There were 58 suicide assessments in the 2 trials in which a specific plan was
elicited from the patient. The most common plans involved medication overdose
(n = 26), using a gun (n = 13), intentional vehicular accident (n = 8), and cutting
oneself (n = 7). There were 75 suicide assessments in the 2 trials in which the
patients reported factors that would prevent them from harming themselves. The
most common preventive factors were the “4 F’s”: family (n = 46), future hope (n
= 17), faith (n = 13), and fear of failing in their attempt (n = 6).
Suicide Attempts
Table 2 reports data on suicide attempts and completed suicides for the 6 trials (1
trial only had data on suicide completions). In the 3,523 depressed patients
enrolled in the 6 trials, there were only 2 known suicide attempts and no
completed suicides. The 2 patients who attempted suicide did so by ingesting
unknown quantities of medication and were in the earlier trials that led to the
algorithm tested in SCAMP and INCPAD. Both had triggered a suicide
assessment. The patient who attempted suicide in ARTIST (A Randomized Trial
Investigating SSRI Treatment) did so shortly after study enrollment and had
relatively severe depressive symptoms (PHQ-9 score of 20). The patient was
determined to be low risk as a result of the assessment, primarily because he did
not have a plan. The assessment was conducted approximately 5 days prior to the
suicide attempt, and, therefore, the patient may not have been at high risk or
suicidal at that time (K.K., MD, unpublished data, 2010). The patient who
attempted suicide in RESPECT had been classified as intermediate risk on her
baseline interview given her thoughts of self-harm but no active plan.  Her
primary care physician already was treating her with paroxetine. After the
overdose, the patient's primary care physician changed her pharmacotherapy to
venlafaxine and referred her to a psychologist for psychotherapy as well.
DISCUSSION
Our study has several important findings. First, the probability of serious
suicidality as manifest by high-risk suicidal ideation, suicide attempts, or suicide
completions is quite low in clinically depressed primary care or medical specialty
patients enrolled in depression treatment effectiveness trials. Second, a simple
algorithm inquiring about the 4 P’s—past attempts, current plans, probability of
an attempt, and preventive factors—can serve as a brief screen for risk
stratification of patients identified as having potential thoughts of self-harm.
Third, even in patients who have such thoughts, specific factors can often be
identified that are currently preventing them from acting on their thoughts, the
most common protective factors being the 4 F’s: family, future hope, faith, and
fear of failing in their attempt.
The low rate of serious suicidal behavior manifest in our 6 trials was only slightly
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higher in the PROSPECT trial of 598 patients with late-life depression, which was
also conducted in a general medical population with an explicit aim of reducing
suicide ; the PROSPECT trial had 3 suicide attempts and 1 completed suicide. A
few cautionary points should be noted. All 6 of our effectiveness trials excluded
patients considered to be seriously suicidal at baseline (of note, suicidal ideation
was not included in eligibility criteria in PROSPECT).
Although this exclusion applied to very few potential study subjects, it means
such patients would not have been enrolled in our effectiveness trials. While it is
likely that such patients would be identified by the P4 screener, the rare
occurrence of suicide attempts and completions in these clinical trials may
underestimate true rates among the entire population of depressed patients in
clinical practice. Also, all patients were enrolled in a clinical trial, which tends to
enhance treatment beyond that which may occur in clinical practice settings.
Clearly, screening for suicidal risk should be done in parallel with optimizing
depression treatment.
A second limitation of our study was the rarity of actual suicide attempts. As
noted, such events are uncommon in clinical practice and even rarer in clinical
trials. Because of this, our findings must be considered largely descriptive until
further validation occurs. Such efforts could include administration of the P4
screener to a sample of more seriously depressed patients (eg, psychiatric
inpatients) or testing with a case-control design in which P4 responses are
compared between patients with and without suicide attempts or suicidal
behaviors. Also, comparing the performance of the P4 screener with longer
suicidality scales is desirable.
Suicidal ideation is clearly an imperfect proxy for suicidal behavior. Certainly,
some patients who are serious about committing suicide hide their plans from
their family, friends, and clinicians or proceed to make an attempt even if their
ideation is disclosed to or detected by the clinician. The fact that suicide remains
an uncommon event relative to the prevalence of depression, particularly in
patients receiving care in medical rather than psychiatric referral settings, makes it
exceptionally difficult to gather sufficient data regarding the sensitivity and
specificity of any measure in detecting actual suicide attempts. Even the data from
multiple large trials that prompted the US Food and Drug Administration (FDA)
to issue a black box warning about antidepressants and suicide risk were based
much more on suicidal ideation than suicidal behavior.
Our study has several strengths. Although based on patients eligible and willing to
enroll in clinical trials, the effectiveness design of the trials increases the
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generalizability of our findings to clinical practice. In contrast to efficacy trials,
effectiveness trials are more pragmatic with fewer exclusion criteria, are less
tightly controlled “real world” administration of treatments, and include a wider
spectrum of patients in terms of age, medical comorbidity, socioeconomic
disparities, and other characteristics. A second strength is both the large number
of patients studied (> 3,500) and the diversity of clinical settings, including both
primary care and medical specialty populations. Third, the structured assessment
algorithm and prospective data collection in the SCAMP and INCPAD trials
allowed us to gather detailed quantitative and qualitative data that further inform
us about the nature of suicidal ideation in depressed medical patients.
The availability of a brief measure for assessing suicidality is especially timely for
several reasons. Depression screening has been recommended by the US
Preventive Services Task Force as long as there are systems in place to enhance
appropriate treatment.  Brief and even ultrabrief measures (2–4 items) have
been found to have excellent operating characteristics for depression
screening.  However, no comparable evidence-based brief screening measure
to assess suicidal ideation has been proposed. In evaluating chest pain, physicians
learn to risk-stratify patients with a few specific questions to identify the urgency
of the situation as well as those patients needing referral and/or hospitalization.
Similarly, clinicians would benefit considerably by having an efficient way for
assessing suicide risk in depressed medical patients that can distinguish the rare
patient that needs urgent “same-day” psychiatric evaluation from the majority of
patients who can have either initial treatment and follow-up in the medical setting
or referral to (or collaboration with) mental health specialists.
A second benefit to having a brief assessment tool relates to recent concerns by
the FDA and others that initiating antidepressant therapy may be associated with a
slight increased risk of suicidal ideation, particularly in adolescents and young
adults.  The algorithm in provides a simple yet structured means of
documenting suicide assessment, both for clinical and medicolegal purposes.
Third, our work may inform current suicide prevention efforts in health care
systems such as the Department of Defense and Veterans Health Administration.
Military personnel and veterans, especially those returning from Iraq and
Afghanistan, have been found to have higher suicide rates than the general
population. For example, the Veterans Health Administration has implemented a
new performance measure requiring a screen for suicidal ideation when veterans
screen positive for depression.
Despite its public health importance, the degree to which suicide is preventable
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remains uncertain.  Nonetheless, there is general agreement that asking
about suicidal ideation is an indicator of high-quality depression care and should
be the standard of practice. While only a small fraction of patients expressing
suicidal ideation actually attempt suicide, the group as a whole is more seriously
depressed and warrants more aggressive treatment and closer follow-up. The fact
that depression is common while completed suicide is rare means that an
individual clinician will encounter hundreds of depressed patients in his or her
lifetime, yet (fortunately) will experience few or no completed suicides. This
necessitates a brief approach to assessing suicide risk that conforms to the realities
of a busy clinical practice,  wherein complex psychosocial issues can be
especially burdensome.  In addition to time constraints, a lack of perceived
competence or comfort in assessing suicidal ideation may be a barrier for some
non–mental health clinicians, a factor that could be addressed by training in a
structured assessment approach. To this end, the brief algorithm developed over
the course of 6 randomized effectiveness trials may be a useful tool for clinicians,
educators, and researchers.
Drug names: paroxetine (Paxil, Pexeva, and others), venlafaxine (Effexor and
others).
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Figures and Tables
Figure 1
Figure 1. P4 Screener for Assessing Suicide Risk
P4 is a mnemonic for the 4 screening questions: past suicide attempt, suicide plan,
probability of completing suicide, and preventive factors. ©Copyright 2010 Kurt Kroenke,
MD.
Any individual who responds “yes” to a question about thoughts of self-harm is asked 4
additional questions—the 4 P’s on past history, plan, probability, and preventive factors.
Shaded responses are those that are more concerning for suicidal ideation.
Table 1
Suicide Algorithms in 6 Randomized Clinical Effectiveness Trials for Depression
in Medical Populations (N = 3,523 subjects)
ARTIST IMPACT RESPECT AIM SCAMP INCPAD
Characteristic
Patients, n 573 1,801 404 186 250 309
No. of
practices
37 18 60 4 11 16
a,b
a
b
31 32 33 34 35
Clinical setting Primary care Primary care Primary care Neurology Primary care Oncology
Population All patients Geriatric All patients Poststroke Chronic pain Cancer
Excluded if
suicidal
Yes Yes Yes Yes Yes Yes
Follow-up, mo 9 24 6 9 12 12
Intervention
group
SSRI
antidepressant
Collaborative
care
Collaborative
care
Collaborative
care
Collaborative
care
Collaborative
care
Control group SSRI
comparator
Usual care Usual care Attention
control
Usual care Usual care
Randomization
unit
Patient Patient Practice Patient Patient Patient
No. of
algorithm
items
3–8 3 10–16 4–10 6–14 5–13
p4 Screener question
Past attempts + + + + + +
Plan + + + + + +
Probability + + + + +
Preventive
factors
+ + + +
Other questions
Risk factors
 Owns gun + + +
 Stockpiles
pills
+ + +
 Lives alone + + +
 Impulsive + + +
 Hopeless + + +
 Uses alcohol + +
 Uses drugs +
When attempt
is likely to
occur
+ +
a
b
b
Recency of
plan
+
Told someone
of suicidal
ideation
+
Patients deemed to be actively suicidal (threshold varied with trial) on eligibility
interview were not enrolled but were referred for immediate care.
Number of items (questions) asked in some algorithms could vary depending on
positive responses and branching points in the algorithm.
Abbreviations: AIM = Activate-Initiate-Monitor, ARTIST = A Randomized Trial
Investigating SSRI Treatment, IMPACT = Improving Mood—Promoting Access
to Collaborative Treatment, INCPAD = Indiana Cancer Pain and Depression,
RESPECT = Re-Engineering Systems in Primary Care Treatment of Depression,
SCAMP = Stepped Care for Affective Disorders and Musculoskeletal Pain.
Symbol: + = item was asked as part of the suicide algorithm for that particular
trial.
Figure 2
Figure 2. Flow Diagram Showing Suicidality Risk Stratification of Subjects Enrolled in the
SCAMP (primary care patients) and INCPAD (cancer patients) Trialsa
A suicide assessment is triggered by a positive response to a question or question(s) during
the research interview about thoughts of self-harm. Subjects who triggered an assessment
more than once during the trial are counted only once in the flow diagram and are classified in
the highest risk category that they achieved. Minimal risk patients are those with neither a
past history of or a current plan for a suicide attempt and who report their probability of
attempting self-harm as “not at all likely.” Lower risk patients report a past history and/or
a
b
a
current plan but indicate their probability of an attempt as “not at all likely” and report factors
preventing them from taking action. Higher risk patients report their probability of an attempt
as “somewhat likely” or “very likely” and/or an absence of factors preventing them from
taking action.
Abbreviations: INCPAD = Indiana Cancer Pain and Depression, SCAMP = Stepped Care for
Affective Disorders and Musculoskeletal Pain.
Table 2
Suicidal Ideation, Suicide Attempts, and Suicide Completions in 6 Randomized
Clinical Effectiveness Trials for Depression in Medical Populations (N = 3,523
subjects)
Trial Subjects,
n
Duration
(mo)
Suicidal Ideation More
Than Minimal Risk (%)
Suicide
Attempts
(n)
Suicide
Completions
(n)
ARTIST 573 9 1.6 1 0
IMPACT 1,801 24 … … 0
RESPECT 404 6 10.0 1 0
AIM 186 9 4.8 0 0
SCAMP 250 12 7.2 0 0
INCPAD 309 12 8.7 0 0
Abbreviations: AIM = Activate-Initiate-Monitor, ARTIST = A Randomized Trial
Investigating SSRI Treatment, IMPACT = Improving Mood—Promoting Access
to Collaborative Treatment, INCPAD = Indiana Cancer Pain and Depression,
RESPECT = Re-Engineering Systems in Primary Care Treatment of Depression,
SCAMP = Stepped Care for Affective Disorders and Musculoskeletal Pain.
Symbol: … = no data.
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